Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC. - Lopez JS; Harrington KJ; Im SA; Lee KW; Postel-Vinay S; Thomas JS; Lukashchuk N; Willis SE; Irurzun-Arana I; Webb B; Nehra J; Lau A; et al. (British journal of cancer, 2026)